Member Info for Hurst10

With Radiopharmaceutical biotech Abdera raising $ 100mill in a Series B,the targeted radiotherapy field is moving forward fast. Hence PointBiopharma nearly testing YTD highs.

Via Affyxell, they have exposure to GenScript ProBio, whom I am sure would like to be part of the AVA revolution.

Avacta nil cost for their holding in Affyxell, work out yourselves The potential value of their stake post an IPO vs the current market cap of the company!!!

https://www.fda.gov/news-events/press-announcements/fda-approves-cell-therapy-patients-blood-cancers-reduce-risk-infection-following-stem-cell

Look what is happening in the world of Stem Cell!
Just the beginning!
Gamida up 100% in days on NYSE:
FDA Approves Cell Therapy for Patients with Blood Cancers to Reduce Risk of Infection Following Stem Cell Transplantation.
Full story to follow, Affyxell IPO documents getting ready, Valuation!!!! Avacta, GenScript Probio and Samsung Ventures some of the very happy shareholders!!

Frustrated early AM calls from the coffee bar: “ prize and size in AVCT? “
Watch our usual friends back on the bid !
Regular size purchases hitting the screen, working orders difficult to hide.

NY looking for next candidate:
Merck & Co. made the first jab, taking Prometheus Biosciences and its bowel disease candidate in a $10.8 billion transaction Sunday. Then GSK struck Tuesday, offering $2 billion for Bellus Health to challenge its fellow pharma dealmaker in the cough market.

The two deals are a long-awaited sign of green shoots in the industry, adding to a fairly short list that includes Pfizer’s $43 billion acquisition of Seagen and Amgen’s $27.8 billion buy of Horizon Therapeutics.

Moody’s Investor Services thinks these are just the start, with M&A activity expected to remain high over the next year to 18 months. Pharmas are trying to restock their pipelines due to approaching patent cliffs and long-term pricing pressure, Moody’s wrote in a Monday sector commentary note.

https://www.trackwise.co.uk/trackwise-to-showcase-ev-battery-interconnect-tech-at-electric-hybrid-vehicle-tech-battery-show-europe-in-stuttgart-germany/

Would expect further guidance on the AVA market and commercial value.
Upgrade from the Diagnostic division, with several conferences coming up and have taken place.
More from Affyxell!
Will be a very interesting Tuesday!!

With FY numbers out next Tuesday, we have continued strong data from the trials, awaiting more news from our Korean partner in the gene therapy area, update from Launch Diagnostic and more news from our JV’s and milestone payments. Not a surprise we continue to see strong buying every afternoon.

These findings are among the first to establish therapeutic prime editing of HSPCs, implying that prime editing and transplanting patient HSPCs may represent a promising therapeutic strategy as a one-time autologous treatment for SCD and other blood disorders.

Prime-Edited Patient Blood Stem Cells Fully Engraft and Rescue Sickle Cell Mice.

Another deal, Glaxo acquiring in the speciality medicines area. $2bill in cash ( 103% premium) for Bellus.

Stand by for after hours prints

Could possible be a case of “ We’re going to need a bigger boat “ !!

The last 20 min 125/ bought

Watch 145 offer being lifted and 150-5 next stop for size.

Buyers having morning swim down in Florida, working orders over the next 4 hours, “size and price” being worked out.Stand by for some nice prints! Will be some Monday opening. We got up to date data on AVA3396 on Sunday, would not be surprise if a RNS is out Monday AM. Do not forget the company wanted to discuss AVA6000 again!! Must be keen!!
The last hour of todays trading, no limit orders!

Avacta’s diagnostic division relevance:
Concern is growing that a new Covid variant behind a rise in cases in India could become dominant in the UK and prompt a new wave of the virus this spring.

The new variant named “Arcturus” is behind a surge of infections in Indiawhere the latest figures show overall Covid case numbers have surpassed 10,000 infections a day and have soared 13-fold in the past month.

Virologist Dr Stephen Griffin from the University of Leeds said Arcturus is growing at a faster rate than other variants and is “rapidly outcompeting” others in India. He added that the new variant, which is now spreading globally, is particularly concerning because of limitations in genomic sequencing and tracking, leaving the UK “completely in the dark” after it stopped publishing ONS Covid case figures last month.

Video update by CEO post AVA3396 presentation and further update on AVA6000.
Video available pre Monday trading!

Of course we also have Prof. Udai Banerji attending as well.